CD274 and neoplasm: We did not observe synergistic effect on killing tumor cells with combination of Pembrolizumab and ERK inhibitor in vitro co-culture system, probably because blocking PD-1 by Pembrolizumab and inhibiting PD-L1 by ERK inhibitor disrupted the same immune pathway of PD-1/PD-L1 axis.